Annovis Bio, Inc. (ANVS)

NYSE: ANVS · IEX Real-Time Price · USD
14.40 -1.12 (-7.22%)
Jan 18, 2022 4:00 PM EST - Market closed
Market Cap116.65M
Revenue (ttm)n/a
Net Income (ttm)-10.28M
Shares Out8.10M
EPS (ttm)-1.40
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume107,710
Open15.19
Previous Close15.52
Day's Range14.10 - 15.48
52-Week Range9.71 - 132.00
Betan/a
AnalystsBuy
Price Target70.00 (+386.1%)
Earnings DateNov 3, 2021

About ANVS

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is ANVS401, which is in Phase 2a clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, Alzheimer's disease in Down Syndrome, and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. T...

IndustryBiotechnology
IPO DateJan 29, 2020
CEOMaria Maccecchini
Employees2
Stock ExchangeNYSE
Ticker SymbolANVS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for Annovis Bio stock is "Buy" and the 12-month stock price forecast is 70.00.

Price Target
$70.00
(386.11% upside)
Analyst Consensus: Buy

News

Annovis Bio Enhances Leadership Team with Two Senior Appointments

Company Appoints Eve Damiano, MS, RAC, as Senior Vice President of Regulatory OperationsCompany Promotes Cheng Fang, Ph.D., to Senior Vice President of Research & DevelopmentBerwyn, Pennsylvania--(Newsf...

1 week ago - Newsfile Corp

Annovis Bio Announces Official Unique Name Buntanetap for Lead Candidate ANVS401

Berwyn, Pennsylvania--(Newsfile Corp. - January 5, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, toda...

1 week ago - Newsfile Corp

Annovis Bio to Participate in the Biotech Showcase and H.C. Wainwright Bioconnect Virtual Conferences

Company to Conduct Virtual One-on-One Meetings During Biotech ShowcaseBerwyn, Pennsylvania--(Newsfile Corp. - January 3, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-s...

2 weeks ago - Newsfile Corp

Annovis Bio CEO Maria Maccecchini Issues Letter to Stockholders

Berwyn, Pennsylvania--(Newsfile Corp. - December 20, 2021) - Annovis Bio, Inc. (NYSE American: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative dis...

4 weeks ago - Newsfile Corp

Annovis Bio Announces Publication of ANVS401 Mechanism of Action in Peer-Reviewed Pharmaceutics

ANVS401 (Posiphen) Inhibits the Translation of mRNAs of Neurotoxic Proteins Responsible for the Progression of Neurodegenerative DiseasesBerwyn, Pennsylvania--(Newsfile Corp. - December 14, 2021) - Anno...

1 month ago - Newsfile Corp

Annovis Bio Announces Transfer of Listing to the New York Stock Exchange

Trading to begin November 18, 2021 with current ticker "ANVS"Berwyn, Pennsylvania--(Newsfile Corp. - November 15, 2021) - Annovis Bio, Inc. (NYSE American: ANVS) ("Annovis" or the "Company"), a clinical...

2 months ago - Newsfile Corp

Annovis Bio Presented At The 14th Clinical Trials on Alzheimer's Disease Conference

With additional data, the primary, secondary, and exploratory endpoints were met in Phase 2a studyBerwyn, Pennsylvania--(Newsfile Corp. - November 12, 2021) - Annovis Bio, Inc. (NYSE American: ANVS) ("A...

2 months ago - Newsfile Corp

Annovis Bio Presents Poster on Mechanism of Action at the 14th Clinical Trials on Alzheimer's Disease (CTAD) Conference

Poster highlighting the mechanism of action for ANVS401 is on display onsite and onlineBerwyn, Pennsylvania--(Newsfile Corp. - November 9, 2021) - Annovis Bio, Inc. (NYSE American: ANVS) ("Annovis" or t...

2 months ago - Newsfile Corp

SHAREHOLDER ALERT: Robbins LLP Investigates Annovis Bio, Inc. (ANVS) for Misleading Shareholders

SAN DIEGO--(BUSINESS WIRE)---- $ANVS #alzheimersdisease--Annovis Bio, Inc. (ANVS) is Accused of Materially Misrepresented the Outcome of its ANVS401 Clinical Trials

2 months ago - Business Wire

Annovis Bio to Present at the 14th Clinical Trials on Alzheimer's Disease (CTAD) Conference

Dr. Maria Maccecchini will present additional Phase 2 data on November 12, 10:25 a.m. ESTA poster highlighting the mechanism of action for ANVS401 will be on display onsite and onlineBerwyn, Pennsylvani...

2 months ago - Newsfile Corp

SHAREHOLER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Annovis Bio, Inc. of Cla...

NEW YORK, Oct. 15, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Annovis Bio, Inc. ("Annovis" or the "Company") (NYSE: ANVS) and certain of its officers...

3 months ago - PRNewsWire

DEADLINE MONDAY ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Annovis Bio, Inc. and ...

Los Angeles, California--(Newsfile Corp. - October 14, 2021) -  The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Annovis Bio, Inc. ...

3 months ago - Newsfile Corp

CLASS ACTION UPDATE for ANVS, HNST and HYZN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Sh...

NEW YORK, NY / ACCESSWIRE / October 13, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholder...

Other symbols:HNSTHYZN
3 months ago - Accesswire

LAWSUITS FILED AGAINST ANVS, EAR and HYZN - Jakubowitz Law Pursues Shareholders Claims

NEW YORK, NY / ACCESSWIRE / October 13, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies wh...

Other symbols:EARHYZN
3 months ago - Accesswire

Kessler Topaz Meltzer & Check, LLP: Important Deadline Reminder for Annovis Bio, Inc. Investors in Securities Fraud C...

RADNOR, Pa., Oct. 13, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that a securities fraud class action lawsuit has been filed against Annovis Bio, Inc. (NYS...

3 months ago - PRNewsWire

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Annovis Bio, Inc. of a Class Action Lawsuit and a L...

New York, New York--(Newsfile Corp. - October 13, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of A...

3 months ago - Newsfile Corp

ANVS LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Annovis Bio, Inc.

New York, New York--(Newsfile Corp. - October 12, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Annovis Bio, Inc....

3 months ago - Newsfile Corp

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of LIVE, ANVS and SAVA

NEW YORK, NY / ACCESSWIRE / October 12, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. ...

Other symbols:LIVESAVA
3 months ago - Accesswire

Final Deadline Approaching on October 18, 2021: Kessler Topaz Meltzer & Check, LLP Reminds Annovis Bio, Inc. Investor...

Radnor, Pennsylvania--(Newsfile Corp. - October 12, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP reminds Annovis Bio, Inc. (NYSE American: ANVS) ("Annovis") investors that a securities fra...

3 months ago - Newsfile Corp

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Annovis Bio, Inc. of a Class Action Lawsuit and a Lead...

New York, New York--(Newsfile Corp. - October 12, 2021) -  The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders of Annovis Bio, Inc. (NYSE Ameri...

3 months ago - Newsfile Corp

MONDAY DEADLINE REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Annovis Bio, Inc. a...

Los Angeles, California--(Newsfile Corp. - October 12, 2021) -  The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Annovis Bio, Inc. ...

3 months ago - Newsfile Corp

ANVS ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 18, 2021 in the Class Action Filed on B...

New York, New York--(Newsfile Corp. - October 12, 2021) -  The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Annovis Bio, Inc. (NYSE American: ANVS) ...

3 months ago - Newsfile Corp

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of SLQT, ANVS and ATIP

NEW YORK, NY / ACCESSWIRE / October 12, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. ...

Other symbols:ATIPSLQT
3 months ago - Accesswire

ANNOVIS BIO Investor Alert: Class Action Lawsuit Filed

Boston, Massachusetts--(Newsfile Corp. - October 11, 2021) - The Thornton Law Firm alerts investors that a class action lawsuit has been filed on behalf of investors of Annovis Bio, Inc. (NYSE American:...

3 months ago - Newsfile Corp

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of YALA, LIVE and ANVS

NEW YORK, NY / ACCESSWIRE / October 11, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. ...

Other symbols:LIVEYALA
3 months ago - Accesswire